Celator Reaches Deal In Suits Over $1.5B Sale To Jazz
A New Jersey federal judge on Thursday pressed the pause button on a pair of proposed shareholder class actions against Celator over its planned $1.5 billion sale to Jazz Pharmaceuticals, after...To view the full article, register now.
Already a subscriber? Click here to view full article